Business Wire

Allianz and Monument Re Complete Sale of Part of Allianz’s Closed Life Book Portfolio in Belgium

1.4.2021 15:30:00 EEST | Business Wire | Press release

Share

The transaction has been approved by the Belgian regulator with effective date April 1st, 2021 and follows the announcement released in August 2020: Allianz Benelux and Monument Re announce closed book portfolio transaction.

With the completion of the transaction, both Allianz Benelux and MAB will now focus on ensuring a seamless transfer for clients and broker partners involved. Therefore, Allianz continues to service the portfolio throughout 2021 and into 2022.

The sale supports Allianz’s strategy in Belgium to actively manage its insurance portfolio towards modern life insurance products with an attractive value proposition for Allianz’s customers. The market share of Allianz in the country remains unchanged at around 6 percent.

Kathleen Van den Eynde, CEO of Allianz Belgium: “We are happy to finalize this transaction. It is an important step in successfully executing our Life strategy to move to modern capital light insurance products, mainly Branch 23. It solidifies our expectations for continued growth by offering innovative products and solutions to our clients, together with our brokers, in Life, Health, Employee Benefits and also in the Property & Casualty business.”

Koen Depaemelaere, CEO of Monument Assurance Belgium: “We are pleased to announce the completion of this transaction. We look forward to welcoming the policyholders to Monument and would like to take the opportunity to assure them of our commitment to maintaining the high quality service and security that they have enjoyed at Allianz. Following earlier acquisitions of four other Belgian portfolios this transaction with Allianz helps us to substantially increase scale and confirms Monument Assurance’s position as a leading consolidator in the Belgian market.”

Note for editors:

About Allianz in the Benelux

Allianz is a global leader in insurance and financial services provision. It is present in over 70 countries, employing more than 147.000 people serving 100 million customers. Allianz is the no. 1 insurance brand in the 2020 Interbrand Global Brand Rankings. In the Benelux, Allianz offers a broad range of insurance products and services for individuals, the self-employed, SMEs and large companies through its network of insurance brokers. In Belgium and Luxembourg, Allianz serves more than 900,000 customers, employs close to 950 people and collects 2.8 billion euros. In the Netherlands, Allianz serves over 1.3 million customers with the help of distribution partners and the direct writer, Allianz Direct. Allianz employs approximately 1,000 people in the Netherlands and collects 1.3 billion euros in gross premiums in that country.

About Monument Re

Monument Re Limited is a life Reinsurance and Insurance Holding Company with a presence in Bermuda, Ireland, Belgium, Luxembourg, the Netherlands, Guernsey and Isle of Man, with branches in Spain, Italy and Germany. Monument Re operates as a reinsurer and acquirer of European asset-intensive portfolios. Through this strategy, Monument Re assumes asset-based risks within its risk appetite and efficiently operates these businesses or portfolios.

Monument Re is subject to Group Supervision by the Bermuda Monetary Authority.

Monument Assurance Belgium is part of the Monument Re Group and operates as a closed book consolidator of life portfolios in Belgium under the supervision of the National Bank of Belgium.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Allianz Benelux N.V.
Paul Möller, Head of Communications Benelux Tel.: +31 (0)88 577 11 06
E-mail: paul.moller@allianz.nl

Fiona Davies at info@monumentregroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a

LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 05:30:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for a global leader in healthcare services. This resulted in faster time to market, modern scalable ecosys

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye